260 related articles for article (PubMed ID: 15303549)
1. [Levosimendan in heart failure].
Scelsi L; Campana C; Ghio S; Monti L; Opasich C; De Feo S; Cobelli F; Orlandi M; Di Pasquale G; Tavazzi L
Recenti Prog Med; 2004; 95(7-8):376-83. PubMed ID: 15303549
[TBL] [Abstract][Full Text] [Related]
2. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
[TBL] [Abstract][Full Text] [Related]
4. The utility of levosimendan in the treatment of heart failure.
Lehtonen L; Põder P
Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
[TBL] [Abstract][Full Text] [Related]
5. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
7. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
8. Patients with advanced heart failure and the effects of levosimendan.
Song ZZ; Ma J
Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
[No Abstract] [Full Text] [Related]
9. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
[TBL] [Abstract][Full Text] [Related]
10. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
11. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
[TBL] [Abstract][Full Text] [Related]
14. Intermittent levosimendan infusions in advanced heart failure: a real world experience.
Ortis B; Villani A; Oldani M; Giglio A; Ciambellotti F; Facchini M; Parati G; Malfatto G
J Int Med Res; 2017 Feb; 45(1):361-371. PubMed ID: 28222634
[TBL] [Abstract][Full Text] [Related]
15. Myocardial efficiency during levosimendan infusion in congestive heart failure.
Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
[TBL] [Abstract][Full Text] [Related]
16. Can we believe in levosimendan?
Follath F
Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
[No Abstract] [Full Text] [Related]
17. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
García González MJ; Domínguez Rodríguez A
Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]